Expression and clinical significance of programmed death ligand 1 in nasopharyngeal carcinoma

  • Authors:
    • Yuan Qu
    • Di Wang
    • Lin Yang
    • Hui‑Ying Liu
    • Wei Cui
    • Yi‑Qun Che
  • View Affiliations

  • Published online on: May 21, 2018     https://doi.org/10.3892/mco.2018.1633
  • Pages: 75-81
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Nasopharyngeal carcinoma (NPC) has the highest incidence of all types of head and neck cancer in China. The present study aimed to investigate the association between the expression of programmed death ligand 1 (PD‑L1) in NPC tissues and clinicopathological features, as well the outcomes for NPC patients. In addition, the association between tissue expression of PD‑L1 and immune components in peripheral blood was assessed. The expression of PD‑L1 was determined by immunohistochemistry, while immune indexes were determined by ELISA and flow cytometry. The positive expression rate of PD‑L1 in NPC patients was 29.2%, and the PD‑L1 expression levels were associated with distant metastasis (P=0.010) and the T‑stage of the primary tumor (P=0.032). The expression of PD‑L1 was associated with the distant metastasis‑free survival of NPC patients (P=0.006). In addition, a statistically significant association of PD‑L1 expression with Epstein‑Barr virus viral capsid antigen IgA (EBV VCA‑IgA; P=0.046) and with CD3‑CD19+ cells (P=0.014) was identified. These results indicated that PD‑L1 may be a potential prognostic biomarker for NPC patients, and that EBV VCA‑IgA and CD3‑CD19+ cells may be useful for predicting PD‑L1 expression when its levels cannot be detected due to the lack of a tumor tissue sample.
View Figures
View References

Related Articles

Journal Cover

July-2018
Volume 9 Issue 1

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Qu Y, Wang D, Yang L, Liu HY, Cui W and Che YQ: Expression and clinical significance of programmed death ligand 1 in nasopharyngeal carcinoma. Mol Clin Oncol 9: 75-81, 2018
APA
Qu, Y., Wang, D., Yang, L., Liu, H., Cui, W., & Che, Y. (2018). Expression and clinical significance of programmed death ligand 1 in nasopharyngeal carcinoma. Molecular and Clinical Oncology, 9, 75-81. https://doi.org/10.3892/mco.2018.1633
MLA
Qu, Y., Wang, D., Yang, L., Liu, H., Cui, W., Che, Y."Expression and clinical significance of programmed death ligand 1 in nasopharyngeal carcinoma". Molecular and Clinical Oncology 9.1 (2018): 75-81.
Chicago
Qu, Y., Wang, D., Yang, L., Liu, H., Cui, W., Che, Y."Expression and clinical significance of programmed death ligand 1 in nasopharyngeal carcinoma". Molecular and Clinical Oncology 9, no. 1 (2018): 75-81. https://doi.org/10.3892/mco.2018.1633